Abiomed to Present at the Stephens 2018 Investment Conference in New York, NY
02. November 2018 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman,...
アビオメッド、2019年度第2四半期の収入を発表、収入は前年を37%上回る1億8,200万ドル (約205億円)
01. November 2018 20:21 ET
|
ABIOMED, Inc.
マサチューセッツ州ダンバース発, Nov. 02, 2018 (GLOBE NEWSWIRE) -- 画期的な心臓回復およびサポート技術のリーディングプロバイダであるアビオメッド (Abiomed, Inc.、 NASDAQ:ABMD) は本日、2019年度第2四半期に1億8,180万ドル (約205億円) の収入を計上し、2018年度同期の1億3,280万ドル (約150億円)...
Abiomed kündigt Rekordumsatz von 182 Millionen USD für das zweite Quartal des Geschäftsjahres 2019 an – eine Steigerung von 37 % gegenüber dem Vorjahr
01. November 2018 20:21 ET
|
ABIOMED, Inc.
DANVERS, Massachusetts, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), ein führender Anbieter bahnbrechender Technologien zur Herzunterstützung und Wiederherstellung der...
Abiomed annonce un chiffre d'affaires record de 182 millions $ pour le deuxième trimestre 2019, soit une hausse de 37 % par rapport au trimestre équivalent de l'exercice précédent
01. November 2018 20:21 ET
|
ABIOMED, Inc.
DANVERS, Massachusetts, 02 nov. 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), un fournisseur majeur de technologies innovantes de récupération et d'assistance cardiaque, a annoncé...
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
01. November 2018 07:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2019...
Abiomed Second Quarter Fiscal 2019 Earnings and Conference Call Notification
11. Oktober 2018 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, November 1, 2018, the Company will release financial results for the second quarter of...
Data Presented at TCT 2018 Shows Use of Impella and Best Practices Increases Cardiogenic Shock Survival
24. September 2018 08:00 ET
|
ABIOMED, Inc.
SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- A new analysis of data from Abiomed's (NASDAQ:ABMD) Impella® Quality (IQ) Database shows a relative increase of 24% in mean survival in acute myocardial...
Abiomed to Showcase Expanded FDA Indications and Next Generation Heart Recovery Products at TCT 2018
19. September 2018 12:53 ET
|
ABIOMED, Inc.
DANVERS, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), the leader in heart recovery, announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT)...
アビオメッド、2019年度第1四半期の収入を発表、収入は前年度比36%増の1億8,000万ドル
26. Juli 2018 18:56 ET
|
ABIOMED, Inc.
マサチューセッツ州ダンバース発, July 27, 2018 (GLOBE NEWSWIRE) -- 画期的な心臓回復およびサポート技術のリーディングプロバイダーであるアビオメッド (ABIOMED, Inc.、NASDAQ:ABMD) は本日、2019年度第1四半期に1億8,000万ドル (約200億円) の収入を計上し、2018年度同期の1億3,250万ドル (約146億9,000万円)...
Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treated
26. Juli 2018 07:30 ET
|
ABIOMED, Inc.
DANVERS, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, announced the Impella 2.5®, Impella CP®...